PEPTIDE SYNTHESIS CORE

肽合成核心

• 批准号: 7959377
• 负责人: Joel Marvin Guthridge
• 金额: $ 7.23万
• 依托单位: OKLAHOMA MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7959377
• 关键词: Active Sites; Amino Acids; Animals; Anthrax disease; Antibodies; Area; Autoantibodies; Autoimmune Diseases; Autoimmune Process; Binding; Binding Sites; Centers of Research Excellence; Chemistry; Cleaved cell; Computer Retrieval of Information on Scientific Projects Database; Core Facility; Data; Epitope Mapping; Foundations; Funding; Gene Expression; Grant; Health Sciences; Human; Immunization; Institution; Left; Length; Liquid substance; Maps; Mentors; Molecular Profiling; Oklahoma; Parents; Peptide Synthesis; Peptides; Phase; Principal Investigator; Proteins; Publishing; Qualifying; Reagent; Request for Applications; Research; Research Personnel; Resources; Science; Screening procedure; Serum; Signal Transduction; Solid; Source; Specialized Center; Specificity; Systemic Lupus Erythematosus; T-Lymphocyte Epitopes; Techniques; Time; United States National Institutes of Health; Universities; base; beta-site APP cleaving enzyme 1; cytokine; disease phenotype; experience; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This portion of the parent application requests the resources to support the Core Peptide Synthesis Facility for the major applications in this proposal, as well as for qualified investigators throughout Oklahoma. This Core Facility will primarily construct peptides, ranging from four to twenty amino acids in length using standard, Fmoc chemistry. These peptides will initially be constructed on solid phase supports, which can either be left in their 96-well format or cleaved to free peptides into the fluid phase. The principal investigator of this core has over 16 years of experience using this technique and has published extensively in this area. (Please see attached biosketch and core references.) Peptides constructed by this Facility have previously been used in B and T cell epitope mapping of human and monoclonal sera, inhibition of enzymatic reactivities and mapping of enzymatic active sites. The Core Facility has synthesized peptides for at least two of the key investigators in the past application, as well as providing key resources and preliminary data for the initial funding of two of the additional start-up projects and several of the newly funded collaborative Anthrax and Specialized Center of Research Excellence in Systemic Lupus Erythematosus projects. This Core Facility will serve as a vital resource for several of the current projects, as well as serving the Cell Signaling Core Facility. A large portion of Dr. Chang's proposal is dependent upon solid phase peptides that will be built in the Peptide Core. The core will build screening (8mers) and confirmatory (4-12mers) overlapping peptides of memapsin-2 to identify the key binding sites of memapsin-2 antibodies. Cleaved peptides can also be synthesized for further functional characterization and animal immunization experiments. In addition, the project of Dr. Centola will focus on identifying autoimmune disease-specific cytokine and/or gene expression profiles. Once expression differences are determined, peptides can be generated to confirm findings at the protein level. Based upon our extensive previous experience in the characterization of autoimmune disease phenotypes, the Core will assist Dr. Sawahla with peptide reagents to determine autoimmune specificities and characterize autoantibody binding profiles. Peptides produced for the signaling core will also be used in the projects of Drs. Rodgers and Jackson. As time and resources allow, the Core Peptide Facility will also be available to other investigators from the Foundation, the University of Oklahoma Health Sciences Center, Tulsa University, Oklahoma State University, Oklahoma University and Oklahoma Christian University.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 父母申请的这一部分要求资源支持本提案中主要应用程序以及俄克拉荷马州合格的调查人员的核心肽合成设施。该核心设施将主要构建肽，使用标准，FMOC化学的长度为四到二十个氨基酸。这些肽最初将在固相支架上构建，该肽可以以96孔格式保留，或裂解以将肽游离到流体相中。该核心的主要研究人员使用该技术拥有超过16年的经验，并在该领域广泛发表。 （请参阅附着的Biosketch和核心参考。）该设施构建的肽先前已用于人和单克隆血清的B和T细胞表位映射，抑制酶促反应率以及酶促活性位点的映射。核心设施在过去的应用中为至少两个关键研究人员合成了肽，并提供了关键资源和初步数据，以最初资助其他两个其他启动项目，以及一些新资助的合作炭疽和一些新资助的协作和专业研究中心，在系统性的lupus erythematososus项目中。 该核心设施将成为当前几个项目的重要资源，并为电池信号核心设施提供服务。 Chang博士的大部分建议取决于将建立在肽芯中的固相肽。核心将构建筛选（8mers）和确认性（4-12mers）重叠的Memapsin-2肽，以识别Memapsin-2抗体的关键结合位点。裂解的肽也可以合成以进一步的功能表征和动物免疫实验。此外，Centola博士的项目将集中在识别自身免疫性疾病特异性细胞因子和/或基因表达谱。一旦确定表达差异，就可以生成肽以确认蛋白质水平的发现。基于我们以前在自身免疫性疾病表型表征的经验中，核心将帮助Sawahla博士使用肽试剂来确定自身免疫性特异性并表征自身抗体结合曲线。为信号芯产生的肽也将用于DRS项目。罗杰斯和杰克逊。随着时间和资源的允许，基金会，俄克拉荷马大学健康科学中心，塔尔萨大学，俄克拉荷马州立大学，俄克拉荷马大学和俄克拉荷马基督教大学的其他研究人员也将提供核心肽设施。